We use cookies on this site. By browsing our site you agree to our use of cookies. Close this message Find out more

Home > For business home > Licensing / commercialisation > Licensing opportunities
More in this section Licensing / commercialisation

Licensing opportunities

This page contains details of licensing opportunities generated from research across the College and based on patent applications or granted patents. For further information on any of these please contact the Business Development Manager listed under each item.

If you are seeking a particular technology or business solution which is not listed here please contact the Head of Research and Business Development.

Artibodies - Protein affinity reagents by rational design

The Artibody technology represents a radically different method of designing protein affinity reagents. Current approaches aim to achieve a high degree of complementarity at the interface between the affinity reagent and the surface of the protein molecule. Devising such an interface is the main challenge in the field of antibody research and development.

In contrast, Artibodies are polypeptides which bind target proteins by displacing surface exposed elements of the target proteins. Artibody technology utilises the fact that some of the surface exposed mobile elements of the protein structure can be displaced by polypeptides with similar or identical sequences. These sequences fit the target protein perfectly, taking advantage of the inherent flexibility in protein structures.

Competitive advantages of the Artibody technology:

  • easy to design Artibody molecules based on the target protein structure or sequence
  • no need to immunise animals, no need to screen huge libraries of recombinant antibodies
  • short polypeptides are easy and cheap to manufacture by chemical synthesis
  • no need for recombinant production, better reproducibility, fewer quality control issues
  • unaffected by denaturing reagents, increased stability compared to immunoglobulins or other protein based affinity reagents
  • smaller size and increased stability makes Artibodies attractive therapeutic drug candidates

This work is the subject of Royal Holloway's PCT patent application no. PCT/GB2010/050838.

We are now looking for partnering opportunities with commercial organisations interested in licensing, consultancy or contract reserch related to this technology.

For further information contact Joanna Cox, Business Development Manager, BioSciences.

Tel: 01784 414969

Novel therapeutics for the treatment of neurological disorder

Work by scientists at Royal Holloway has resulted in the identification of novel therapies for neurological disorders based around the actions of Valproic acid (VPA). VPA is widely used for the treatment of epilepsy, bipolar disorder and migraine. Despite its widespread use the mechanism of action of VPA has been poorly understood.

The scientists at Royal Holloway used a simple biomedical model to determine the cellular effects of VPA. With this approach, they determined several biochemical mechanisms for VPA and identified VPA related compounds with substantially higher potency for these effects. When further tested using in vitro and in vivo animal epilepsy models the compounds identified caused up to a three-fold increase in seizure protection. A range of novel compounds related to the structure of VPA have now been patented, and it is anticipated that these will show increased efficacy and reduced side-effects in comparison with the parent compound.

We are now looking for commercial partners to develop this further.

For further information contact Joanna Cox, Business Development Manager, BioSciences.

Tel: 01784 414969

Enhanced performance SQUID based on the Andreev probe

Making use of unusual materials and a novel geometry, scientists from Royal Holloway have fabricated a Quantum non-demolition interference device for ultralow noise ultrasensitive vector magnetometry and as a read out of superconducting quantum circuits.

The device is much more sensitive (*3000) than a conventional SQUID. The sensitivity improvement is obtained by the fact that no electrical connection is required to achieve a measurement. An implication of this is that with no introduced noise, measurements can be taken much faster - minutes rather than days. Also, as the device requires no direct electrical connection to make a measurement there is no back action so quantum bits can be measured.

The new device  is based on the Andreev probe. A number of modifications were carried out to make the probe a complete quantum nondemolition (QND) interference device.

For further information contact Martin Kelly, Head of Research  and Business Development. 

Tel: 01784 414968 

RFID Attack Detector (RAD)

The RFID Attack Detector (RAD) is an intelligent sniffer (radio receiver) designed to detect attempted attacks on RFID, contactless smart card and NFC based systems in real time.

The Information Security Group Smart Card Centre has been carrying out research and providing expert advice on detecting attacks on contactless/smartcard systems for several years.

The RAD incorporates this research and expertise into a practical device that can be used to detect and intercept attacks using emulated, cloned or counterfeit devices. It can detect unusual physical activity by the device, for example deviations from expected radio frequency or timing behaviour. It can also detect variations from expected interaction protocols, which may be attempts to explore the RFID system protocols and/or obtain cryptographic keys.

The RAD is not only applicable to transport systems, but in many other areas where contactless technology is increasingly important and is under continuous scrutiny from hackers.

A working prototype has been built with a realistic form factor for practical deployment and has been successfully demonstrated to RFID technology user organisations.

The RAD is the subject of International Patent Application No. PCT/GB2010/000167.

We are now seeking partners to license the technology and/or to participate in shared development.

For further information contact David Wells, Business Development Manager, ICT.

Tel: 01784 414931


Find an expert


Comment on this page

Did you find the information you were looking for? Is there a broken link or content that needs updating? Let us know so we can improve the page.

Note: If you need further information or have a question that cannot be satisfied by this page, please call our switchboard on +44 (0)1784 434455.

This window will close when you submit your comment.

Add Your Feedback